● Recruiting

Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis

Condition: Cancer · Sponsor: Shenzhen Geno-Immune Medical Institute

PhasePhase 1/Phase 2

Planned participants100

Who can joinAll sexes, 1 Year to 80 Years

Healthy volunteersNo

About this study

The primary objective of this study is to verify the safety of antigen-specific T cells (CAR-T) and engineered immune effector cytotoxic T cells (EIE) modified by immunoregulatory genes and immune modified dendritic cell vaccine (DCvac) in the treatment of neurofibromatosis or schwannoma.

This description comes directly from the study's public registry record.

Talk to the study team

Lung-Ji Chang, PhD · +86 0755-86573763 · c@szgimi.org

Always discuss trial participation with your own doctor first.

Locations (1)

Shenzhen Geno-immune Medical Institute

Shenzhen, Guangdong, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04085159